Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Protagonist Therapeutics, Inc | Chief R&D Strategy Officer | Common Stock | 168K | $4.13M | $24.63 | Nov 16, 2022 | Direct |
Protagonist Therapeutics, Inc | Chief R&D Strategy Officer | Stock Option (right to buy) | 0 | Nov 16, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PTGX | Protagonist Therapeutics, Inc | Nov 16, 2022 | 10 | $232K | 4 | Nov 17, 2022 | Chief R&D Strategy Officer |
PTGX | Protagonist Therapeutics, Inc | Feb 28, 2022 | 1 | -$51.4K | 4 | Mar 2, 2022 | Chief Scientific Officer |
PTGX | Protagonist Therapeutics, Inc | Feb 15, 2022 | 2 | $0 | 4 | Feb 17, 2022 | Chief Scientific Officer |
PTGX | Protagonist Therapeutics, Inc | Aug 17, 2021 | 3 | -$694K | 4 | Aug 19, 2021 | Chief Scientific Officer |